• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

    11/12/24 4:56:16 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SAGE alert in real time by email
    SC 13G/A 1 UnitedStates_13G__SageTherap.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* (Name of Issuer) Sage Therapeutics Inc (Title of Class of Securities) Common Stock (CUSIP Number) 78667J108 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 78667J108 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 37,811 (7) Sole dispositive power 5,675,830 (8) Shared dispositive power 84,619 (9) Aggregate amount beneficially owned by each reporting person 5,760,449 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 9.43% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Sage Therapeutics Inc Item 1(b) Address of issuer's principal executive offices: 55 Cambridge Parkway Cambridge, MA 02142 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 78667J108 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 5,760,449 (b) Percent of class: 9.43% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 5,760,449 (b) Percent of class: 9.43% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 37,811 (iii) Sole power to dispose or to direct the disposition of: 5,675,830 (iv) Shared power to dispose or to direct the disposition of: 84,619 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, t* he securities referred to above were not acquired and are not held for the pur* pose of or with the effect of changing or influencing the control of the issuer* of the securities and were not acquired and are not held in connection with or* as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 12, 2024 THE VANGUARD GROUP By: /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration
    Get the next $SAGE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SAGE

    DatePrice TargetRatingAnalyst
    3/11/2025$5.00Underperform
    BofA Securities
    11/21/2024$4.00Underperform → Sector Perform
    RBC Capital Mkts
    10/10/2024Mkt Perform
    Raymond James
    10/4/2024$10.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    7/30/2024$16.00 → $10.00Buy → Hold
    TD Cowen
    7/25/2024$18.00 → $12.00Overweight → Neutral
    JP Morgan
    5/29/2024$15.00Neutral
    Robert W. Baird
    5/29/2024$8.00Sell
    Citigroup
    More analyst ratings

    $SAGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities resumed coverage on SAGE Therapeutics with a new price target

      BofA Securities resumed coverage of SAGE Therapeutics with a rating of Underperform and set a new price target of $5.00

      3/11/25 7:43:31 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SAGE Therapeutics upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded SAGE Therapeutics from Underperform to Sector Perform and set a new price target of $4.00

      11/21/24 7:42:56 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on SAGE Therapeutics

      Raymond James resumed coverage of SAGE Therapeutics with a rating of Mkt Perform

      10/10/24 8:30:27 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

      SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

      11/14/24 6:14:58 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

      SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

      11/12/24 4:56:16 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

      SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

      11/12/24 10:34:18 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Quirk Michael C. was granted 2,000 shares, increasing direct ownership by 7% to 29,108 units (SEC Form 4)

      4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

      4/2/25 4:06:40 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Quirk Michael C. claimed ownership of 27,108 shares (SEC Form 3)

      3 - Sage Therapeutics, Inc. (0001597553) (Issuer)

      4/2/25 4:06:25 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Shiferman Gregory L. covered exercise/tax liability with 79 shares, decreasing direct ownership by 0.26% to 30,680 units (SEC Form 4)

      4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

      3/26/25 4:36:43 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SAGE
    Leadership Updates

    Live Leadership Updates

    See more
    • Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

      Achieved $13.8 million in ZURZUVAE® (zuranolone) collaboration revenue in the first quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 21% increase from the fourth quarter Sustained growth in shipments to women with postpartum depression; Greater than 3,000 shipments in first quarter of 2025 (22% increase from fourth quarter) Cash, cash equivalents, and marketable securities of $424 million as of March 31, 2025; Cash runway expected to support operations to mid-2027 Strategic alternatives review process remains ongoing Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025. "We

      4/29/25 4:05:00 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025

      Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that it will host a live webcast on Tuesday, April 29, 2025, at 4:30 p.m. ET to review first quarter 2025 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indic

      4/15/25 6:30:00 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics Announces R&D Leadership Transition

      Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company's product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis. "I would like to extend my sincerest gratitude to Laura for her leadership and dedication to advancing innovation for patients with debilitating brain health conditions," said Barry Greene, Chief Executive Officer of

      3/4/25 4:15:00 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics Announces R&D Leadership Transition

      Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company's product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis. "I would like to extend my sincerest gratitude to Laura for her leadership and dedication to advancing innovation for patients with debilitating brain health conditions," said Barry Greene, Chief Executive Officer of

      3/4/25 4:15:00 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics Appoints Jessica Federer to Board of Directors

      Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230316005117/en/Jessica Federer (Photo: Business Wire) "We are thrilled to have Jessica join our Board of Directors. Jessica is a champion for patients and has a track record of innovation in data and digital transformation which will be a key future growth driver for the industry," said Barry Greene, Chief Executive Officer at Sage Therapeutics. "Jessica's innate curiosit

      3/16/23 6:30:00 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer

      Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Laura Gault, MD, Ph.D. as Chief Medical Officer. In her new role, Dr. Gault will focus on advancing Sage's current and emerging product pipeline through all stages of development. "We are thrilled to have Dr. Gault join Sage to lead the development and delivery of our pipeline of potential new medicines and be a partner in our mission to improve the lives of people affected by brain health disorders," said Barry Greene, Chief Executive Officer at Sage Therapeutics. "Dr. Gault's vision, experience and deep commitment to this field of med

      11/1/22 7:30:00 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    Financials

    Live finance-specific insights

    See more
    • Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

      Achieved $13.8 million in ZURZUVAE® (zuranolone) collaboration revenue in the first quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 21% increase from the fourth quarter Sustained growth in shipments to women with postpartum depression; Greater than 3,000 shipments in first quarter of 2025 (22% increase from fourth quarter) Cash, cash equivalents, and marketable securities of $424 million as of March 31, 2025; Cash runway expected to support operations to mid-2027 Strategic alternatives review process remains ongoing Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025. "We

      4/29/25 4:05:00 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025

      Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that it will host a live webcast on Tuesday, April 29, 2025, at 4:30 p.m. ET to review first quarter 2025 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indic

      4/15/25 6:30:00 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates

      Strong first full year of launch with sustained growth in shipments to women with postpartum depression; Nearly 2,500 shipments in fourth quarter of 2024 (21% increase from third quarter) $11.4 million in ZURZUVAE® (zuranolone) collaboration revenue in the fourth quarter of 2024 and $36.1 million for the year ended December 31, 2024 (50% of the net revenues recorded by Biogen) Cash, cash equivalents, and marketable securities of $504 million as of December 31, 2024; Cash runway expected to support operations to mid-2027 Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "We are

      2/11/25 4:05:00 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    SEC Filings

    See more
    • SEC Form 10-Q filed by Sage Therapeutics Inc.

      10-Q - Sage Therapeutics, Inc. (0001597553) (Filer)

      4/29/25 4:18:21 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Sage Therapeutics Inc.

      8-K - Sage Therapeutics, Inc. (0001597553) (Filer)

      4/29/25 4:13:02 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Sage Therapeutics Inc.

      DEFA14A - Sage Therapeutics, Inc. (0001597553) (Filer)

      4/24/25 4:20:03 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • August 4, 2023 - La FDA aprueba el primer tratamiento oral para la depresión posparto

      For Immediate Release: August 04, 2023 El día de hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó Zurzuvae (zuranolona), el primer medicamento oral indicado para tratar la depresión posparto (DPP) en mujeres adultas. La DPP es un episodio depresivo grave que generalmente ocurre después del parto, pero también puede comenzar durante las últimas etapas

      8/8/23 9:34:19 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • August 4, 2023 - FDA Approves First Oral Treatment for Postpartum Depression

      For Immediate Release: August 04, 2023 Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health

      8/4/23 6:50:31 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care